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UbjecGws, To assess generalizability of the Bypass Angioplasty 
Revascularization Investigation (BARI), we conducted a separate 
stady comparing revasselarization in U.S. and BARf hospitals. 
kkgroarrd. The BAH trial is a multicenter investigation 
comparing initial revascuiarization with percutaneous translumi- 
nal coronary angioplasty and coronary bypass graft surgery in 
patients with symptomatie multivessel coronary disease. 
Me#wds. All revascnlarization procedures during 5 consecutive 
workdays were surveyed at 75 U.S. hospitals offering coronary 
angioplasty and bypass sttrgery and at all BARi hospitals. Data 
cokcted were demographics, extent of disease and type of current 
aad previous revasctdarization. 
Resa.?& At both U.S. and RARI hospitals, 57% of all revascu- 
larization procedures were coronary angiopiasty and 43% were 
bypass surgery. The U.S. hospitals bad more patients with singie- 
vessel disease, acute myocardial infarction and primary proce- 
dures. Other characteristics .Rre similar. The majority of revas- 
cularization procedures were angtoptasty for single-vessel disease 
The Bypass Angioplasty Randomization Investigation (BARI) 
is a multicenter, randomized clinical trial designed to evaluate 
whether initial revascularization with percutaneous translumi- 
nal coronary angioplasty is as effective and safe as coronary 
artery bypass graft surgery for patients with severe myocardial 
ischemia and muhivessei coronary disease. Between August 
1988 and August 1991, 1,829 patients suitable for both proce- 
dures were randomized at 18 clinical centers (2 merged, 
resulting in 17 active centers). Study end points include 5-year 
mortality; death or Q wave myocardial infarction; functional 
status; and quality of life, A registry of 2,013 eligible but not 
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0J.S. 32% vs. BARI 25%) and bypass surgery for triple-vesseli 
disease QUS. 31% vs. BARf 31%). Overall, the choke between 
hypass surgery and angioplasty was similar in BARI and U.S. 
hospitals (adjusted odds ratio [OR] 1.0, p = 0.914). However, 
older patients were more likely and younger patients Iess likely to 
undergo [bypass surgery in BAR1 versus U.S. hospitals (older 
patients: adjusted OR 1.6, p = 0.031; younger patients: adjusted 
OR 5.6, p = O.QZS). The BARB protocol wotdd have exch&d 65% 
of all candidates For revascularization, for whom indications 
already exist for angioplasty or bypass surgery, and anotber 23%, 
for whom angioplasty lwosid be contraindicated for individual 
lesions. 
Cbmlusimw. Patients undergoing coronary revascularization in 
BARI and US. hospitals were getterally similar, as was ttte cttoice, 
hetweeu Qpes of revascularizatien. Results from the BARI trial 
appfy to -360 (12%) candidates fop coronary revascutarization/ 
workday. 
fJ An Cdl Car&l IY%$;2&6094 
randomized patients is also being followed, along with 422 
patients who represent a 6% sample angiographically unsuit- 
able for the trial. Details of the protocol (1) recruitment (2) 
patient characteristics (3) and technical aspects of the proce- 
dures (4,5) have been reported previously. 
The ultimate goal of any clinical trial is to provide guidance 
to clinicians who treat patients in the general community. To 
accomplish this goal, an unbiased comparison of the treat- 
ments under study must be provided. This comparison is 
usually achieved by randomization. The resuIts of the BARI 
randomized trial wilt provide clinicians with information on the 
relative ethcacy of coronary angioplasty versus bwss surgery 
in selected patients with multivessei coronary disease. The 
impact of these results will depend on the degree to which the 
patients studied in BAR1 are representative of patients seen in 
hospitals across the United States. In an effort to address this, 
a study was conducted to determine the basic features of 
contemporary practice of coronary revascularization in U.S. 
hospitals that perform both angioplasty and bypass; surgety ’ 
Specifically, we sought to answer three primary questions: .l) 
Are the patients seeking revascularization at BARI paiticipat- i iZI 
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ing hospitals ditferent from those seeking care elsewhere, as 
has been suggested (67) to be the case for randomized clinical 
trials? 2) Are determinants of treatment decisions made by 
physicians at BAR1 hospitals similar to those at U.S. hospitals? 
3) What proportion of all patients undergoing coronary revas- 
cularization procedures at U.S. and BARI hospitals do the 
patients studied in the BARf trial represent? 
Methods 
Hospital characteristics. The American Hospital Associa- 
tion Iisted 779 U.S. hospitals that offered both coronary 
angioplasty and bypass surgery in 1989. These 779 hospitals 
were ordered by the Metropolitan Statistical Area code, and 
every seventh hospital was asked to participate in a l-week 
survey of all coronary revascularization procedures performed. 
A total of ill hospitals were selected to participate, and 75 
agreed, Participating hospitals were compared with nonpwtic- 
ipating hospitals a‘,cording to bed size, atliliation with a 
medical school, administrative control (private nonprofit, for 
profit, federal government and nonfederal government) and 
geographic location (New England, Mid-Atlantic, South At- 
lantic, North East Central, South East Central, North West 
Central, South West Central, Mountain and Pacific States). 
None of these hospital characteristics were significantly related 
to participation in the survey, although New England, Mid- 
Atlantic and South Atlantic sites had slightly higher participa- 
tion rates. 
Patient characteristics. At each hospital, all patients un- 
dergoing coronary revascularization were counted for a period 
of 5 consecutive workdays, Monday through Friday. In the case 
of a planned staged procedure, only the first stage was counted. 
However, an individual patient could still be counted twice if 
an unsuccessful procedure and subsequent revascularization 
both occurred during the 5-day period covered by the survey. 
This occurred in -2.5% of patients. For each patient, the 
following data were collected: age, race, gender, number of 
diseased vessels, number of totally occluded vessels, left main 
coronary artery disease, myocardial infarction <24 h before 
procedure and the current and previous procedures (bypass 
surgery and coronary angioplasty [balloon angioplasty or an- 
gioplasty with a new interventional device, such as a stent, 
rotoblator or laser]). Hospital surveys were staggered between 
March 1992 and May 1994. Instructions for the survey, includ- 
ing detailed definitions for all data items, were given to each 
hospital. Angiographic definitions were based on those used in 
the BAR1 protocol (1). As a rule, the principal investigators 
assigned catheterization laboratory or operating room person- 
nel to collect data, One of the authors (M.E.C.) provided 
oversight of data collection and was available to answer any 
questions. A nominal reimbursement was provided for data 
collection, although participation was largely a result of gen- 
erosity and scientific interest on the part of the physicians and 
surgeons who practice coronary revascularization at each 
institution (see Appendix). 
To provide comparative data from BARI hospitals, all 
clinical centers were asked to complete an identical survey on 
all patients undergoing revascularization during the week of 
March 17 to 21,1993. This survey was conducted nearly 2 years 
after recruitment for the BARI trial ended. 
Statistical methods. Differences in patiert characteristics 
at U.S. and BAR1 hospitals were examined with the chi-square 
statistic for proportions and the Wilroxon statistic for contin- 
uous data (8). The number of procedures surveyed were 
sulhcienr to detect population differences, such as 5?& versus 
10% and 42.5% versus 50%, with 0.8 probability. The Mantel- 
Haenszel (9) statistic was used to test for an :rrsoeiation 
between the hospitals (U.S. vs. BARI) and the revasculariza- 
tion strategy used (coronary angioplasty vs. bypass surgery) 
while controlling for number of diseased vessels, loft main 
coronay itrtery disease and previocs Rrccedure. 
Treatment decision making between BARI and U.S. hos- 
pitals was compared by computing the odds of a patient 
receiving bypass surgery versus coronary angioplasty. Odds 
ratios > (<)l indicate that bypass surgery was used more (less) 
frequently in BARI hospitals than in U.S. hospitals. Lugistic 
regression analysis was used to estimate odds ratios, and Wald 
statistics (10) were used to determine whether they departed 
from unity. 
Hospital characteristics. Hospital characteristics and re- 
vascuiarization procedures counted during the 5&y surveys 
were compared for U.S. versus BAR1 hospitals (Table 1). The 
BAR1 hospitals were generally larger, located on the East 
coast and affiliated with a medical school, and none were listed 
as for-profit institutions. The U.S. sites on average performed 
13.7 procedures/5-day work week compared with 29.5 proce- 
dures/week at BAR1 hospitals (p < 0.001). Despite this large 
difference in revascularization volume, the relative use of 
bypass surgery versus coronary angioplasty at U.S. hospitals 
closely resembles that observed at BAR1 hospitals. In both 
surveys, angioplasty accounted for -57% of all revasculariza- 
tion procedures (50% for balloon angioplasty, 7% for angio- 
plasty with new devices), and bypass surgery for the remaining 
43%. Throughout the remainder of this report, procedures 
with devices, whether alone or in conjunction with balloon 
angioplasty, are included under angioplasty. 
Patient characteristics. Ciinical character&&s of the pa- 
tients are presented in Table 2. The median age of the patients 
(64 years at US. hospitals, 63 years at BAR1 hospitals) was not 
significantly different. Other demographic characteristics were 
also similar between U.S. and BARI hospitals. About 26% of 
patients were women and 5% African-American, Patients at 
U.S. hospitals had fewer diseased vessels (p = 0.027), had 
fewer previous procedures (p = 0.006) but were more likely to 
have had an acute myocardial infarction ~24 h before the 
procedure (p = 0.005). 
Choice between bypass surgery and cowmary aogioplasty. 
The frequency of revascularization strategy for one-, two- and 
three-vessel disease is displayed in Figure 1. Angioplasty for 
Table 1. Characteristics of Participating Hospitals (75 U.S. and 
17 BARI) 
U.S. Hospitals BAR1 Hospitals 
(%? (a) 
-I__ -____ 
Hospital characteristics 
No. of beds 
~:300 23 f: 
30-394 31 1s 
400-499 13 0 
500+ 31 77 
Medical school affiliation 63 100 
Geographic region 
East 33 65 
Central 43 35 
West 24 0 
?,da:i~istriirive amtrol 
Govcrnmenlh~onfcJcral 8 29 
Government/fcdcr;tl 6 12 
Profit 17 0 
Nonprofit 69 59 
Pcpalation density 
Urban 96 loo 
Rural 4 0 
Revascularization procedures 
No. (meanlhospital) 1,!!?5 (13.7) 5ot (29.5) 
96 CA3G 42.1 43.7 
%: PTCA (no new d&cc) so.4 49.9 
5% New device” 7.4 6.4 
*Includes new devices in conjunction with percutaneous transluminnl coro- 
nary angiopiasty (PICA) as well as those performed alone. BAR1 = Bypass 
Angioplasty Revascularization Investigation; CABG = coronary artery bypass 
graft surgery. 
single-vessel disease accounted for 32% of procedures at U.S. 
hospitals and 25% at BARI hospitals. In both U.S. and BARI 
hospitals, bypass surgery for triple-vessel disease accounted for 
31% of all procedures. Angioplasty for double-vessel disease 
ranked third highest at both U.S. and BARI hospitals, followed 
by triple-vessel angioplasty and double-vessel bypass surgery. 
Very few bypass surgery procedures for single-vessel disease 
were reported. When current procedures were cross-classified 
with previous procedures, the most striking observation was 
that the majority of patients with triple-vessel disease treated 
by angioplasty hzd previous intervention (53% in U.S. vs. 67% 
in BARI hospitals), especially bypass surgery (43% in U.S. vs. 
52% in BARI hospitals). The prevalence of previous proce- 
dures was also high in patients with single-vessel disease 
undergoing bypass surgery. In this small patient group, previ- 
ous coronary angioplasty was reported in 46% at U.S. hospitals 
and 64% at BARI hospitals. This previous procedure presum- 
ably necessitated the bypass surgery reported in the survey, 
possibly on an emergency basis. 
Table 3 explores how number of diseased vessels, left main 
coronary artery disease and previous revascularization influ- 
enced the selection of revascularization procedure. For pa- 
tients with triple-vessel disease (no left main involvement) 
without a previous procedure, the percentage of surgical 
revascularization was 85% at U.S. hospitals and 83% at BARI 
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Table 2. Demographic and Angiographic Characteristics of Patients: 
MI Kevascularization Procedures 
U.S. Hospiiais BAR1 Hospitals 
(IS = 1,025j (I! = 501) 
Median (yr) age 64 63 
Age -3;s yr 50 47 
African-American 5.4 4.4 
FtZKlk 26 71 
Vessel disease” 
SiSlgk 34 27 
Double I? 30 
Triple 39 42 
LMCA 10 io 
2 I total occlusion 37 so 
MI witbin 24 ht s 4 
Previous proccdurcst 
NOSlt! 73 65 
PTCA only$ I6 20 
CA3G I1 15 
-.-- 
*p < 1!.015, ?p < 0.01 for chi-square statistic, U.S. versus BAR1 Lospit& 
$With or without new devices. Unless othcwisc indicated, data prcscnted xc: 
percenl of p,:ticnts. LMCA = left main corona? artery: MI = myocardial 
infarction; otbcr abbreviations as in Table 1. 
hospitals. If patients with triple-vessel disease (no left main 
involvement) had previous coronary angioplasty only, these 
rates were 67% and 61%, but if !hey had previous bypass 
surgery, additional surgery was selected for 41% in both 
samples. Generally, for patients with previous bypass surgery 
or single-/double-vessel disease without left main involvement, 
the choice of rwascularization was predominantly aqioplasty. 
The presence of left main disease increased the likelihood of 
bypass surge9 to ?~90%, unless patients already had a previous 
bypass. Overall, revascularization choices by these character- 
istics were not significantly different between U.S. and BAR1 
hospirals (Mantel-Haenszel, p ‘= 0.80). 
In addition to the extent of coronary disease, left main 
involvement and previous procedure, the choice between types 
Figure 1, Distribution of current procedure by vessel disease (VD). 
Distribution of previous procedures are shown below each bar, 
CAW = coronary artery bypass graft surgery; PTCA = percutiineous 
transluminal coronary angioplasty with or without new devices. 
612 DETRE ET AL. 
SURVEY OF CORONARY REV.4SCI_ILARIZ.~TIQN 
JACC Vol. 28, No. 3 
Sqmmber 1996:609-15 
Table 3. Percentage of Patients Undergoing Bypass Surgery Classified by Left Nain Coronary Artery 
Disease. Previous Procedures and Zxtenr of Vessel I%ease* - - 
Previous Procedures 
US. Hospitals 5ARl Hospitals -- 
PTCA? PTCA? 
None Only CABG Nvap Ch!y CAEG 
(%) (5%) (%) (5%) (%I (9%) 
Vessel disease (no LMCA) 
Single 5 18 6 4 IS - 
Double 32 28 16 37 30 13 
Triple 85 67 31 83 61 41 
LMCA disease 91 90 46 gri - 43 - 
*Percentages for <IO patients not shown: For BARI hospitals, 0 of 6 patients with single-vessel disease (VD) (no left 
main coronary artery disease) and previous bypass surgery, and 3 of 3 patients with left main disease and previous 
coronary angioplasty, underwent bypass urgery. i‘With or without new devices. Other abbreviations as in Tables 1 and 2. 
of revascularization was intluenced by acute myocardial infarc- 
tion, total occlusion, age and raee but not gender (Table 4). 
However, patient age was the only factor that was significantly 
associated with different treatment choices between BARI and 
U.S. hospitals. At BARI hospitals, patients ~6.5 years old 
underwent bypass surgery more often than in U.S. hospitals 
(odds ratio [OR] 1.5, p = O.Ull) but less frequently if they were 
<6.S years old (OR 0.8, p = 0.148). The latter became 
significant after adjustment was made for other patient char- 
acteristics (adjusted OR 0.6, p = 0.028). Associations observed 
for other racial groups and for myocardial infarctions ~24 h in 
Table 4 were not statistically significant. For all patients, the 
odds of undergoing bypass surgery in BAR1 and IJ.S. hospitals 
were nearly the same (OR 1.1, p = 0.530) which remains true 
after adjusting for patient characteristics (ac-ljusted OR 1.0, p = 
0.914). 
Size of target pogulatiun. To determine the percent of all 
revascularization procedures to which BARI results are appli- 
cable, the major BARI exclusion criteria were tabulated for all 
procedures surveyed at both U.S. and BARI hospitals (Table 
5). Patients meeting more than one exclusion criteria were 
counted once for the first criterion to appear in Table 5 (top to 
bottom). According to BARI criteria, the following revascu- 
larizations would not be inclnded: 27% to 34% for single-vessel 
disease; 18% to 26% for patients who had a previous proce- 
dure; and 7% to 8% for left main coronary artery disease. 
Another 2% to 5% would have been excluded for an acute 
myocardial infarction or age >80 years. These exclusions 
Table 4. Odds of Undergoing Bypass Surgery in BAR1 Versus US. Hospitals According to Patient Char~ctcrktics 
No. of Pts ‘3 CABG Odds Ratio - 
U.S. Hospital: BAR1 Hospitak U.S. Hospitals BARI Hospitals Unadjusted Adjusted* - 
Overall 1,021t 501 42.0 43.7 1.1 1.0 
Age <65 yr 515 265 40.4 25.1 0.8 0.6 (p = 0.028)$ 
Age ~65 yr 506 233 43.7 S3.6 1.5 (p = O.Oll)$ 1.6 (p = 0.031)$ 
White 918 461 42.7 44.9 1.1 1.0 
African-American 55 22 36.4 31.8 0.8 0.7 
Other racial group 4x 18 35.4 27.5 0.7 1.8 
Male 752 366 41.0 42.6 I.1 1.0 
Female 269 135 45.0 46.7 1.1 1.0 
No MI ~24 h 941 481 43.1 44.3 1 .o 0.9 
MI ~24 h 80 20 22.5 30.0 15 3.0 
No total occlusion 639 299 33.2 31.8 0.9 0.8 
Total occlusion 382 202 56.8 61.4 1.2 1.2 
No prior procedure 748 327 45.5 48.9 1.1 1.0 
Prior PTCA only8 159 98 34.0 34.7 1.0 0.9 
Prior CABG 114 76 30.7 32.9 1.1 0.8 
IVD (no LMCA) 34x 137 7.5 8.0 1.1 1.0 
2VD (no LMCA) 24-i 142 29.2 33.1 1.2 1.2 
3VD (no LMCA) 326 171 75.5 70.2 0.8 0.8 
LMCA disease 100 51 85.0 80.4 0.7 0.8 
*Logistic regression was used to adjust for age, gender, race, myocardial infarction 124 h, total occlusion, previous procedure and vessel disease; interaction of 
previous procedure with vessel disease was also included, except when those effects were tested. flour patients excmdcd because of missing information, $Gnly p values 
50.05 are shown, IWith or without new devices. Pts = patients; other abbreviations as in Tables 1 to 3. 
JACC Vol. 26, No. 3 DETRE ET AL. 
September 1996~609-15 
613 
SURVEY OF COT-SNARY REVASCULARIZATION 
Table 5. Presence of BARI Excluskms Among 
Revaswlarization Procedures 
Exclusions (in hierarchic order) 
US. Hospitals 
(I? = 1,025) 
(%) 
BARi Hospitals 
(n = 501) 
(a) 
None 3s 38 
IVD 34 27 
Previous procedures 18 26 
LX.4 disease 8 7 
Acute MI 3 1 
Age 280 “r 2 1 .- 
Abbreviations as in Tables 2 and 3. 
account for 65% and 62% of the volume of revascularizations 
performed at U.S. and BAR1 hospitals, respectively. For the 
remaining 35% to 38%. eligibility- in the BARI trial would have 
depended on the suitability of lesions for coronary angioplasty 
by American Heart Association/American College of Cardiol- 
ogy criteria (11) and the judgmcqt of the interventionalist. 
Collection of data on detailed angiographic appearance of 
lesions and how they affected treatment decision making were 
beyond the scope of the present study. Instead, WC can 
estimate from the BARI screening experience (2) that exclu- 
sions based on angiographic criteria amount to about two- 
thirds of the remaining eligible patients. Thus, approximately 
12% of all patients undergoing coronary revascularization are 
the population to which BARI and other similar trials (12-15) 
for multivessel disease are applicable. In absolute terms, these 
trials apply to roughly 300 sevascularization procedures/ 
workday, assuming 660,000 procedures (based on 1993 Na- 
tional Centers of Health Statistics, unpublished data, personal 
communicaFion) and 260 workdays/year. 
Discussion 
Our survey exa.mined three facets of contemporary coro- 
nary revascularization practice: 1) the similarity of patient 
characteristics in U.S. and BARI hospitals; 2) whether deter- 
minants of the choice between bypass surgery and coronary 
angioplasty arc sinilar in U.S. and BAR.1 hospitals; and 3) the 
proportion of patients in U.S. and BARI hospitals with char- 
acteristics similar to those studied in the BAR1 trial. 
Patient characteristics. No significant difference was found 
in the distribution of aor 
undergoing coronary re- 
,:nder or race among patients 
_ 1 ,rizaFion at a typical U.S. hospi- 
tal compared with a BARI hospital; nor were there significant 
differences for the presence of left main coronary artery 
disease or a completely occluded coronary artery. However, 
patients with single-vessel disease and an acute myocardial 
infarction were more prevalent in U.S. hospitals (p = 0.027 
and p = 0.005, respectively). Presumably, more patients 
present with acute myocardial infarction in community hospi- 
tals than in tertiary care referral centers that comprise I3ARI. 
Also, referral centers would be somewhat more likely to treat 
patients with multivessel disease and a pre:ious procedure. 
However, these differences were small: 27% versus 30% for 
double-vessel disease; 39% versus 32% for triple-vessel dis- 
ease; 16% versus 20% for previous coronary angioplasty only 
and 11% versus 15% for previous bypass surgery, 
Choice between bypass surgery and coronary angioplasty. 
The distribution of revascuiarization choice by vessel disease 
was similar in U.S. and BAR1 hospitals, although somewhat 
more coronary angioplasty for single-vessel disease was per- 
formed in U.S. hospitals. The most common types were 
angioplasty for single-vessel disease and bypass surgery for 
triple-vessel disease. Conversely, the least frequent were an- 
giup&, for iriple-vcsse? disease and bypass surgery for singic- 
vessel disease. These, we assume, were mainly to correct 
unsatisfactory short- or long-tern! results from the other 
procedure. 
We found no significant difference in the choice between 
surgical and percutaneous intervention in U.S. and BAR1 
hospitals when we considered the number of diseased vessels, 
1efF main coronary artery involvement and previous proce- 
dures. Bypass surgery was performed for the majority of 
patients with triple-vessel disease or left main disease who did 
not have previous bypass surgery. Otherwise, coronary angio- 
plasty was the preferred procedure. Thus, at both U.S. and 
BAR1 hospiFals, the choice of percutaneous procedures dom- 
inated two ends of the spectrum-less severe disease or disease 
complicated by a previous procedure, the latter most likely 
involving vein grafts. For the latter, the choice of angioplasty 
might be dictated by the higher risk associated with a second 
bypass surgery operation (16). 
Choice of revascularization strategy could further be pre- 
dicted by a logistic regression model to adjust for all observed 
patient characteristics. Using this model, we confirmed that 
overall, U.S. and BARI hospitals made the same choices 
between types of revascularization. However, in BAR1 hospi- 
tals, younger patients were less likely to undergo bypass 
surgery than older patients. This was not true in U.S. hospitals. 
Gender and race played the same role in the strategy choice at 
U.S. and BARI hospitals. 
Size of target population. Our surveys show that -12% of 
all patients with coronary revascularization performed in U.S. 
and in BAR1 hospitals would have been eligible for random- 
ization in the BAR1 trial. This number may seem small, but it 
must be put in the context of why BAR1 and similar trials were 
initiated. The use of coronary angioplasty for patients with 
multivessel disease has grown since the 1980s without guidance 
from properly controlled comparisons wiFh bypass surgery. 
Consequently, in the late 198Os, several trials were organized 
to compare the safety and efficacy of bypass surgery and 
angioplasty for patients with multivesse1 disease and severe 
angina or ischemia where both treatments are reasonable 
alternatives. At the time it was not considered necessary or 
ethical to make a scientific comparison of angioplasty and 
bypass surgery with a randomized clinical trial among certain 
subgroups of patients. For many patients with single-vessel 
disease, angiaplasty was generaliy accepted as the treatment of 
choice; however, for patients with ieft main coronary artew, 
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disease or complex coronary artery lesions, an@oplasty was 
considered contraindicated. It would also have been dificult to 
justify or accomplish randomization among patients with mui- 
tivessel disease who had a previous procedure. Nevertheless, in 
absolute terms the number of patients to whom the results of 
BARI and similar trials will apply is considerable: 300 patients/ 
workday. 
Additional randomized trials should be considered for 
some subgroups of patients excluded from the BAR1 trial. 
Patients with previous coronary angioplasty or bypass surgery 
represent a large group of patients in whom many questions 
remain regarding appropriate strategies for follow-up testing 
and therapeutic interventions. Although angioplasty generally 
is the favored intervention for many patients with single-vessel 
disease, the limited thoracotomy approach for bypass is attrac- 
tive, especially for proximal left anterior descending coronary 
artery lesions, and should be tested in the Future by properly 
controlled trials. Recent results from a lipid-lowering trial (17) 
emphasize the importance of continued study of angiopiasty 
versus medical therapy for patients with less extensive disease 
who do not require bypass surgery. 
influence of past clinical trials. The similarity in coronary 
revascularization practice across U.S. and BARI hospitals was 
unexpected because institutional characteristics were different 
between the two groups of hospitals. Most important, the 
average BARI hospital performed twice the volume of coro- 
riary revascularization procedures than the average U.S. hos- 
pital. Uniformity in the selection between bypass surgery and 
coronary angioplasty as a strategy most likely speaks to the 
strong influence of past randomized clinical trials. The early 
findings that bypass surgery was superior to medical treatment 
in patients with left main coronary artery disease (18) and in 
other high risk patients such as those with triple-vessel disease 
(19), as well as the lack of a mortality benefit with bypass 
surgery for single,,vessel disease (20,21) are reflected in current 
bypass surgery practice. In mid-1993, when the surveys were 
carried out, trial results of angioplasty versus bypass surgery 
for multivessel disease, which could have influenced the use of 
angioplasty in such patients, had not yet been reported. 
Study limitations. The comparabilitqr found between revas- 
cularization practice at hospitals participating in the BARI 
trial and at typical U.S. hospitals should be interpreted in the 
context in which the comparison was made. With regard to 
patient descriptors, our data were simple and limited. We did 
not compare refined angiographic appearance of lesions, mea- 
sures of left ventricular function or the clinical manifestations 
that served as reasons for revascularization. We have no 
information ran comorbidities. Most important, we did not 
attempt to qbtain details of the treatment strategy used in 
performing the procedures, which would include the frequency 
of internal mammary grafts used, number of vein grafts, 
number of lesions or vessels attempted by coronav angioplasg 
or the completeness of revascularization achieved. It is possi- 
ble that the two surveys would have revealed differences in 
these characteristics or in the success or complication rates 
resulting from the procedures. 
Conclusions. Hospitals that participated in the BARI trial 
generally perform coronary revascularizations in similar types 
of patients and use similar indicators for the choice between 
procedures as do typical U.S. hospitals. These results should 
put to rest the general claim that studies conducted at aca- 
demic or research institutions are necessarily unrepresentative 
and thus not applicable to the whole medical system. Results 
from the BAR1 trial will apply to 12% of all revascularization 
candidates for whom bypass surgery and coronary angioplasty 
are reasonable alternatives. 
We are grrateful toJames M. Klingensmitb. ScD, who guided us in the design and 
pilot tesling of the U.S. Universe Surveys, and to Antonetta Spatolisano for her 
efforts, which improved the participation rate of the institutions in the U.S. 
survey. We extend our gr&tude and thanks to all the investigators at each 
hospital who participated in the smveys. 
Appendix 
Participating Hospitals and Privzcipal bnvestigators 
U.S. hospitals AMI Frye Regional Medical Cctr&r, Hickory, NC: Richard A. 
Carlton, MD. Alexandzia Hospital Alexandria, VA: Harry Schwartz, MD. Ana- 
heim Memotin HosDital, Anaheim, Cjl: David M. Weinbere. MD. Barnes 
Hospirul, Saint Lords: MO: Philip Ludbrook, MD. Baton Rouge Eerzeral Medical 
Cerllcr, Baton Rozzge, LA: Harris LaDpin, MD. B&ham & Women’s Hospital, 
Boston, M4: Gilbert H. Mudge, MD. l&z Mawr Hos$tal, Byn Mawr, PA: Rbbert 
S. Boova, MD, Jack L. Martin, MD. Cilarleston Arecl Medical Clzarleston, WV: 
Donald Lillv. MD. Co~lev Memorial Hosoital. Aurora. IL: Kirk Kruse. J. D. 
Adams, RCir’T. Dallas’ Cburzg HospitaljP~rk&i, D&s, TX W. Steve Ring, 
MD. Deaconess Medical Center, Billings3 MT: J. Scott Millikan, MD. Deaconess 
Regional Medical Center, Spokane, WA: Michael Hinner, MD, FACC. Delray 
Community Hasp&r/, Delray Be& FL: Michael Davidson, MD. Department of 
Veterans Aflairs Medical Center, 0k;khoma City OK: Eliot Schectcr, MD. Garfield 
Medical Center, Monterq Park, CA: S. Eugene Margolis. MD. Good Samaritan 
Hos&al, Cincinnati, OH: R, Rath, MD. R. Gbiser, MD. J. T. Schreiber. MD. 
D. ‘Buckley, MD. Gortlieb Menz&af lfospital, &elroie Park, IL: Patricia 
O’Connor, RN, MSN, CCRN. Gmm Horpitalof Clzicugo, Chicago, IL: S. Gill, MD. 
Greenville Memorial Hospilal, &envdle, SC: H. G. Parker, MD. Grossmont 
Hospiral, La Mesa, CA: R. K. Goldberg, MD, D. Jinich, MD, H. Gomez-Engler, 
MD. HCA St. Mark’s Hosnital, Salt Lake Citv, UTZ F. Clvde Null. MD. FACP. 
Harris Methodist-HiB Hdspital, Bedford, Ti: David E&n, MD,‘Don ‘Rogers, 
MD. Hennepin COZZIZIY Medical Center, Minneatmlis. MN: Timothy D. Henry, 
MD. Humana Hospi&Aurora, Auroq CO: Dennis J. Battock, hiD. Human; 
Hospital-Lucerne, Orlando, FL: Bonrrie Dawson, RN. Humana Hospital-Metro, 
San Antonio. TX: L. Prasad Vemulaoalli. MD. FACC. Huntintion Memorial 
Hospita/, Pasadena, CA: Joel W. He&r, hiD, FACC. I<erte;ing cedical Center, 
Kettering ON: Bruce Hymor, MD. L&land Regiurlal MEdical Center, Lakeland, 
FL: Ron Vlietstra, MD. Lancuster General $@a[ Lancaster, PA: Seth J. 
Worley, MD. Ocleran Medical Cente: Wheaf Ridte, CO: E. Lance Walker, MD. 
~Marqzz&e General Hospiral, Marqzze~tc, &fk Stephen Cdmpbell, John drider. 
Medical College ofl/irRinia, Richmond. I/A: Michael Cowlcy, MD. Medical College 
of GeoRia, Auncsta, G.4: Marius Sharnn. MD. Medicul ~Collc~e of Ohio, Toledo. 
6ti M&k W. %urket, MD. Mercy Hasp&l of Scranton, Scmitont PA: Gerald i. 
Tracy, MD. Miami Heart InsUute, Miami Beuch, FL: James R. Margolis, MD. 
Mozmt Aubzzm Hospital. Cambridge, MX Stanley A. Forwand, MD, Alan D. 
Hilgenberg, MD. Mt. Sinai Medical Center, New York, NY: Louis Teichhoiz, MD, 
Randall Griepp, MD. N. T. Enloe Memozial Hospital, Cftico, CA: Pete Magnus- 
sun, MD, Jeffrey P. House, RCVT. Presbyterian/Monte~ore Hospital, Pittshzqh, 
PA: J. Shaver, MD, B. G. Denys, B. Griffith, MD. Presbsferian Communi!y 
Hmpital, Whittier, CA: Richard Parks, MD. Rednzond Rrgionai iv&&d Ce&c 
Rome, GA: Frank D. Stegall, MD. Resecrch Medical Center. Kansas City, M& M. 
Eugene Kendall, MD. Rouge tilley Medical Center, Medford, OR: Stephen L. H. 
Fredrickson. RT, Brian Gross, MD. St. Elimbeth ~ospird Medical Center, 
Lufuyelfe, IN: Kathy J. Smitli, RT. St. Jo/m’s Hospital, Sptin@iel~ IL: James T. 
Dove, MD. St. Joseph Hosp$a[, Lexington, KY: Bill Harris, MD. St. Joseph’s 
Hospital, Marshfield, WI: W. 0. Myers, MD, J. W. E. Douglas-Jones, MD, R. A. 
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Reinhart, EAD. St. Joseph HospituI, Omaha, h’E: Jetfrey Sugimoto, >MD. St. Joseph 
Hospital, Syracuse, My: Lewis Johnson, MD. St. Joseph HospitaL Wkhita, KS: 
Daniel Tatpati, MD. St. Luke Hospital-East Iowa Hean, Cedar Rapids, L4: T. 
Langager, MD, M. N. Payvandi, MD, L. J. Cook, MD, D. A. Rater, MD, J. 
Tatkon-Coker, MD, W. C. Meffert, MD, W. W. Strong, Jr., MD, I. M. Ievett, 
MD. St. Peter’s Hospital, Albany, NY: Jonathan DeSantis, MD, Joseph Mcllduff, 
MD. St. Thomas Hospital, Nashville, TN: M. W. Sprouse, RN, CPQA, R. Sharp 
Decker, RN, BSN. CIiFton Meador, MD. St. I/intent Charity Hospital Cleveland, 
OH James Sechler, MD. St. &tcent Medical Center, Los Angeles- CA: Jan N. 
Stem. Oscar Maoidson, MD. St. Vincent’s Medical Cetrrer, Brideeoorr. C?? Edward 
J. K&in&i, !k. Santa Batbam Cottage Hospital, Santa”&&a, CA: Kit 
Robbins, RT. Shands Hospitai. Gainsville, FL: Richard Conti, MD. South Miami 
HospitaL Micmi, FL: Dan Krauthamer, MD. Sutter Memotial Hospital, Sacra- 
mento, CA: Mark Winchester, MD. Theda Clark Regional Me&al Center, 
Neenah, WI: Colleen Schmidt, MSN. Thomas k&son University Hospital, 
Philadelphia, PA: Sheldon Goldberg, MD, Richard N. Edie, MD. Tours It@ 
iMtV. New Orfeans, LA: Roberto E. Quintal, MD. PhD. Truman Memorial 
Vetkms HospitaL &&&Ga, MOz P. Robert’ Meyers, MD. Tucson Medical 
Center, Tucson AZ: Mike Wolfe, RT. United Hospital Grand Forks, ND: Noah 
Chelli& MD.~L’nivetsity of Maryland Medical System, Baltimore, MD: Joseph S. 
McLaughlin, MD, Connie McRilI. MD. Vetemns A&& Medical Centen Dallas, 
‘Ix: Paul A. Gravbum. MD. Vetemns .4fairs Medical Center. San Franctico. CA: 
Fraser M. Keith: h4D. Vetemns Admirkration Medical Center, Memphis, TN: 
Kogansdi B. Ramanathan, MD. Wadley Regional Medical Center, Teratkana, 
7XyJames 0. Wright III, MD> Gregory K. Ho&on, MD. WashoeMedicalCenter, 
Reno, NV: Theodore Bemdt, MD. West Houston Medical Center, Houston TX 
Akira Nishikawa. MD. 
BARI elioicai centsrs Bellevue Hospital/New Yorh University Medical Center, 
Neal York Citv, NY: Frederick Feit, MD. Boston Universitv Medical Center, Boston, 
MA: Alice Jacobs, MD. Brown Univetsi@ho& IslandHospital, Providence, RI: 
David 0. Williams, MD. Cleveland Clinic Fotaufation, Cleveh& QH: Patrick L. 
Whitlow, MD. Duke University Medical Center, Durham, NC: Robert M. Cal& 
MD. Harvard UnivetsityiBeth Israel HospitaL Boston, MA: Donald S. Bairn, MD. 
Jewish Ho.&al Saint Louis, MO: Ronald J. Kronz, MD. Maine Medical Center, 
Portland Mb3 Mirle A. Kel!e!t, Jr., MD. .&yo Cl&, Roches6~, MN Michael 
Mock. MD. Medical College of Qeinia, Ri&mond, VA: Michael 3. Cowiev. MD. 
Montreal Heart Institute, .@on&al,-Quebec, Canaa’az Martial Bourassa, MD. New 
York Medical College, Valhalla, NY: Melvin Weiss, MD. Saint Louis University 
HosoitaL Saint Louis. MO: Bernard R. Chaitman. MD. The Toronto Hosnital 
Toktto; Ontatio, danada: Leonard Schwartz, MD. Unive@v of Alabama 
Medical Center, Bbmingham, AL: William J. Rogers, h4D. University of Massa- 
chusetts, Worcester, &f% Bonnie H. Weiner, MD. University of Michigan, Ann 
Arbor, ,uI: Ber:ram Pitt, MD. 
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